Literature DB >> 18158573

Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.

Alamtaj Samsami Dehaghani1, Alireza Fotouhi Ghiam, Marjan Hosseini, Sareh Mansouri, Abbas Ghaderi.   

Abstract

Screening for breast and ovarian cancers are required due to the late stage at diagnosis and poor survival. Serum CA125 and CA15-3 are important cancerdetecting agents in patients with ovarian and breast cancers, respectively. Elevation of CA125 and CA15-3 level correlates with malignant and non-malignant conditions. Moreover, a series of individual characteristics affect the serum level of these markers. The objective of the present study was to evaluate CA125 and CA15-3 levels in cancer-free postmenopausal women to investigate the impacts of patient parameters on the serum level of these markers. 203 subjects were studied prospectively. Serum CA125 and CA15-3 assessment was done subsequent to the direct interview. The associations between marker levels and presenting features were examined. CA125 and CA15-3 levels were elevated in 35 (17.2%) and 12 (5.9%) of persons, respectively. A higher CA125 level was associated with advanced age (p = 0.046), while a lower level was correlated with hormone replacement therapy (HRT) and having smoking habits (p = 0.000 and p = 0.01, respectively). CA15-3 level was remarkably lower amongst oral contraceptive (OCP) users (p = 0.03). Serum marker levels were not significantly related to menarche age, age at menopause, height, weight, BMI and parity. Serum CA125 is imperative indicator for malignancies of the ovary; however, personal and medical factors influence its serum level. A fair interpretation of results must be due to an accurate attention to the individual characteristics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158573     DOI: 10.1007/bf02940317

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

Review 1.  "Extracts from "Clinical evidence": Menopausal symptoms.

Authors:  J Rymer; E P Morris
Journal:  BMJ       Date:  2000-12-16

2.  Factors influencing serum CA 125 levels in normal women.

Authors:  S Grover; M A Quinn; P Weideman; H Koh
Journal:  Obstet Gynecol       Date:  1992-04       Impact factor: 7.661

Review 3.  [Tumor markers: essential diagnostic tools for radiologists].

Authors:  Hiroyuki Kayaba
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  2003-03

4.  An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery.

Authors:  M Takami; H Sakamoto; K Ohtani; T Takami; K Satoh
Journal:  Cancer Lett       Date:  1997-12-16       Impact factor: 8.679

5.  Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.

Authors:  C Crump; M W McIntosh; N Urban; G Anderson; B Y Karlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-10       Impact factor: 4.254

Review 6.  Prevention of cancers of the breast, endometrium and ovary.

Authors:  Malcolm C Pike; Celeste Leigh Pearce; Anna H Wu
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

Review 7.  Breast cancer screening controversies.

Authors:  Beverly B Green; Stephen H Taplin
Journal:  J Am Board Fam Pract       Date:  2003 May-Jun

Review 8.  Risk factors and risk reduction of breast and ovarian cancer.

Authors:  Cecile T M Brekelmans
Journal:  Curr Opin Obstet Gynecol       Date:  2003-02       Impact factor: 1.927

Review 9.  Climacteric: concept, consequence and care.

Authors:  Nimit Taechakraichana; Unnop Jaisamrarn; Krasean Panyakhamlerd; Sukanya Chaikittisilpa; Khunying Kobchitt Limpaphayom
Journal:  J Med Assoc Thai       Date:  2002-06

Review 10.  Progress and challenges in screening for early detection of ovarian cancer.

Authors:  Ian J Jacobs; Usha Menon
Journal:  Mol Cell Proteomics       Date:  2004-02-05       Impact factor: 5.911

View more
  6 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

3.  Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma.

Authors:  Jennifer M Watson; Photini F Rice; Samuel L Marion; Molly A Brewer; John R Davis; Jeffrey J Rodriguez; Urs Utzinger; Patricia B Hoyer; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

4.  How to Use CA-125 More Effectively in the Diagnosis of Deep Endometriosis.

Authors:  Marco Aurelio Pinho Oliveira; Thiers Soares Raymundo; Leila Cristina Soares; Thiago Rodrigues Dantas Pereira; Alessandra Viviane Evangelista Demôro
Journal:  Biomed Res Int       Date:  2017-06-04       Impact factor: 3.411

5.  Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.

Authors:  Renée T Fortner; Allison F Vitonis; Helena Schock; Anika Hüsing; Theron Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Giuseppe Matullo; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; Elisabete Weiderpass; Inger Torhild Gram; Mie Jareid; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; María Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Jenny Brändstedt; Annika Idahl; Kay-Tee Khaw; Naomi Allen; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Daniel W Cramer; Rudolf Kaaks; Kathryn L Terry
Journal:  J Ovarian Res       Date:  2017-03-20       Impact factor: 4.234

6.  Do serum biomarkers really measure breast cancer?

Authors:  Jonathan L Jesneck; Sayan Mukherjee; Zoya Yurkovetsky; Merlise Clyde; Jeffrey R Marks; Anna E Lokshin; Joseph Y Lo
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.